|
Other issues |
Leading articles
Safety and medicines
PJ 2010;284:2
Be careful what you wish for
PJ 2010;284:2
News feature
Local initiatives to improve drug safety
PJ 2010;284:7-8
Products
Product news
PJ 2010;284:9
DRUG ALERT: Ondansetron
PJ 2010;284:9
DRUG ALERT: Amiodarone
PJ 2010;284:9
Letters
Letters for 2/9 January
PJ 2010;284:10-14
Agenda
Why a fair culture of error reporting is best for patients and for pharmacists
PJ 2010;284:15-18
Interview
Steve Williams
Designated and fully funded posts are needed to ensure medicines safety
PJ 2010;284:17
Gillian Cavell
Understand how medicines are seen and used to develop safe practices
PJ 2010;284:18
Articles
How patient safety is being improved
PJ 2010;284:19-20
Executing the Royal Pharmaceutical Society’s medicines safety policy
PJ 2010;284:21
Phortress: the smart antitumour agent which induces its own metabolism
PJ 2010;284:23-24
Learning and development
Drug interactions and gout treatment
PJ 2010;284:22
Reviews (books)
After the war on drugs: blueprint for regulation
by Stephen Rolles
PJ 2010;284:25
Why us? How science rediscovered the mystery of ourselves
by James Le Fanu
PJ 2010;284:25
Palliative pharmacy care
edited by Jennifer M. Strickland
PJ 2010;284:25
Meetings
Prescribing Observatory for Mental Health (POMH-UK) and the National Patient Safety Agency
Improving medicines management for patients with mental health problems
PJ 2010;284:26
Joint Pharmaceutical Analysis Group and the Pharmaceutical Analysis Sciences Group
The science and regulation of packaging
PJ 2010;284:27-28
Footler
A day for promoting braille
PJ 2010;284:29
A ghostly figure haunting the mountain mists
PJ 2010;284:29
Problem of hereditary disease in isolated island populations
PJ 2010;284:29
The Society
MEP: Medicines, ethics and practice | January 2010 amendments
PJ 2010;284:31
